Skip to main content

Table 4 Patient characteristics among 3 groups

From: Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

    

P

Characteristics

Non-transplant (n= 67)

MRD+ (n= 15)

MRD− (n= 40)

Non-transplant vs MRD+

Non-transplant vs MRD−

MRD− vs MRD+

Gender, n (%)

   

0.112

0.353

0.360

 Male

34 (50.7)

11 (73.3)

24 (60.0)

   

 Female

33 (49.3)

4 (26.7)

16 (40.0)

   

Age, years

   

0.384

0.248

0.931

 Median (range)

27.0 (9.0, 65.0)

26.0 (7.0, 65.0)

26.5 (3.0, 63.0)

   

Hyperploidy, n (%)

3 (4.5)

1 (6.7)

2 (5.0)

0.722

0.901

0.808

Hypoplodiy, n (%)

1 (1.5)

0 (0)

1 (2.5)

0.634

0.710

0.537

Complex karyotype, n (%)

4 (6.0)

0 (0)

2 (5.0)

0.332

0.833

0.378

iAMP 21a, n (%)

1 (1.5)

1 (6.7)

0 (0)

0.240

0.438

0.099

ETV6-RUNX1, n (%)

1 (1.5)

0 (0)

0 (0)

0.634

0.438

NA

E2A-PBX1, n (%)

1 (1.5)

0 (0)

0 (0)

0.634

0.438

NA

MYC mutation, n (%)

1 (1.5)

0 (0)

0 (0)

0.634

0.438

NA

HOX11 mutation, n (%)

1 (1.5)

0 (0)

0 (0)

0.634

0.438

NA

KMT2A rearranged, n (%)

3 (4.5)

1 (6.7)

4 (10.0)

0.722

0.264

0.702

BCR-ABL1, n (%)

11 (16.4)

3 (20.0)

8 (20.0)

0.739

0.639

1.000

Ph like, n (%)

1 (1.5)

1 (6.7)

3 (7.5)

0.240

0.113

0.916

IgH rearranged, n (%)

1 (1.5)

0 (0)

0 (0)

0.634

0.438

NA

IKZF1 mutation, n%

3 (4.5)

3 (20.0)

4 (10.0)

0.037

0.264

0.322

Poor-risk cytogeneticsb, n (%)

18 (26.9)

6 (40.0)

15 (37.5)

0.312

0.249

0.865

Good-risk cytogeneticsc, n (%)

2 (3.0)

0 (0)

1 (2.5)

0.492

0.883

0.462

Primary refractory to chemotherapy, n (%)

17 (25.4)

7 (46.7)

14 (35.0)

0.101

0.288

0.428

Total number of relapses before CAR-T

   

0.148

0.120

0.633

 Median (range)

1 (0, 6)

1 (0, 2)

1 (0, 3)

   

Prior lines of therapy

   

0.519

0.491

0.250

 Median (range)

4 (2, 15)

4 (2, 9)

3 (2, 9)

   

Prior allo-HSCT, n (%)

22 (32.8)

2 (13.3)

1 (2.5)

0.133

< 0.001

0.115

Extramedullary infiltration, n (%)

9 (13.4)

2 (13.3)

1 (2.5)

0.992

0.060

0.115

Platelet count before CAR-T, 109/L (N = 66 + 14 + 38)

   

0.511

0.186

0.799

 Median (range)

130 (15, 412)

139 (12, 302)

140 (21, 389)

   

PLT < 1*LLN before CAR-T, n (%) (N = 66 + 14 + 38)

28 (42.4)

4 (26.7)

11 (27.5)

0.337

0.172

0.979

LDH > 1*ULN before CAR-T, n (%) (n = 66 + 14 + 38)

26 (39.4)

6 (40.0)

19 (47.5)

0.810

0.293

0.647

Blast cells in bone marrow before CAR-T

   

0.802

0.867

0.731

 Median (range)

22.5% (0, 97.0%)

6.6% (0.1%, 89.4%)

22.3% (0, 90.0%)

   

CAR-T cell dose, 106/kg

   

0.340

0.302

0.881

 Median (range)

3.0 (0.3, 25.0)

5.4 (1.0, 11.1)

5.0 (0.1, 30.4)

   

Source of CAR-T cells, n (%)

   

0.438

0.046

0.208

 Autologous

51 (76.1)

12 (80.0)

38 (95.0)

   

 Recipient-derived allogenic

9 (13.4)

2 (13.3)

1 (2.5)

   

 Donor-derived allogenic

6 (9.0)

0 (0)

0 (0)

   

 Third-party

1 (1.5)

1 (6.7)

1 (2.5)

   
  1. aiAMP21 intrachromosomal amplification of chromosome 21
  2. bPoor-risk cytogenetics are defined as hypodiploidy, KMT2A rearranged, t(v;14q23)/IgH rearranged, t(9;22)(q34;q11.2): BCR-ABL1, complex karyotype, Ph-like, and iAMP21
  3. cGood-risk cytogenetics are defined as hyperdiploidy, and t(12;21)(p13;q22): ETV6-RUNX1
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us